Search
Hexaminolevulinate
go.drugbank.com/drugs/DB06261ApprovedInvestigationalHexaminolevulinate is manufactured under the brand Cysview® by Photocure ASA. In Europe, Hexaminolevulinate is marketed under the brand Hexvix®. … invasive papillary cancer of the bladder for patients suspected or known to have lesion(s) on the basis of a prior cystoscopy.
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … [A244225] It was approved by the FDA on January 10, 2022, under the name QUVIVIQ.[L39660] as the second orexin receptor antagonist approved to treat insomnia following [suvorexant].
Siponimod
go.drugbank.com/drugs/DB12371ApprovedInvestigationalIt was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings.
Arbutamine
go.drugbank.com/drugs/DB01102ApprovedArbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in
Oxybenzone
go.drugbank.com/drugs/DB01428ApprovedOxybenzone is an organic compound used in sunscreens. It is a derivative of benzophenone. It forms colorless crystals that are readily soluble in most organic solvents. It is used as an ingredient in sunscreen and other cosmetics because...
Mixtures: Skin Care Prescription, DOCTOR WHITE Advanced Radiance UV Shield SPF 50Felbamate
go.drugbank.com/drugs/DB00949ApprovedAlternatively, it is used to treat partial and generalized seizures associated with Lennox-Gastaut syndrome in children. It has a weak inhibitory effect on GABA receptor binding sites. … In particular, in the adult patient population, it can be employed to treat partial seizures (with and without generalization).
Fludeoxyglucose (18F)
go.drugbank.com/drugs/DB09502ApprovedInvestigationalIt is administered by intravenous injection. … Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with
Phentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigationalThis initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers … [A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeDepemokimab
go.drugbank.com/drugs/DB18846ApprovedInvestigational[A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.
Linezolid
go.drugbank.com/drugs/DB00601ApprovedInvestigational[L32965] Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050 … Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-(((S)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide